A citrullinated peptide vaccine targeting ENO1 (citENO1 vaccine) in triple-negative breast cancer (TNBC) mouse models showed synergistic effects with PD-1 blockade, significantly inhibiting tumor growth and improving survival compared with controls [91]. This evidence concerns the gene ENO1 and neoplasm.